Outcome of Cord-Blood Transplantation from Related and Unrelated Donors

Gluckman, Éliane; Rocha, Vanderson; Boyer-Chammard, Agnès; Locatelli, Franco; Arcese, William; Pasqüini, Ricardo; Ortega, Juan José López; Souillet, G; Ferreira, Eurípedes; Laporte, Jean; Fernández, M.N.; Chastang, Claude

doi:10.1056/nejm199708073370602

Cited by 1,153 publications

(301 citation statements)

References 25 publications

Supporting

Mentioning

281

Contrasting

Unclassified

Order By: Relevance

“…We also found no significant difference in the outcome with different sources of transplant in our patients which is comparable to other studies that advocate the use of unrelated cord blood with great effect in patients who are candidates for HCT but lack a suitable sibling donor [29,35]. Milano et al documented in his study that especially for pre transplant minimal residual disease patients, transplantation with cord blood donor was associated with the similar overall survival as with an HLA-matched, un related donor [36,37]. Chinese also came up with a similar result and also noticed a lower incidence of chronic GVHD in cord blood donor transplant compare to unrelated donor and with a similar outcome with a suitable sibling [38].…”

Section: Discussionsupporting

confidence: 76%

Factors Influencing the Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Single Institution Results from Saudi Arabia

Al‐Sweedan¹,

Siddiqui²,

Jafri³

et al. 2017

J Blood Lymph

View full text Add to dashboard Cite

Medical records of 73 patients with AML who underwent HCT, 2005HCT, -2011. The OS was 51.8% and the EFS were 48%. Median follow-up time for the cohort was 50.667 ± 2.4 months (95%CI: 45.9-55.4). 39 patients were alive with a median follow-up time of 50.1 months (Min: 1.8, Max: 111.8). Sixteen patients survived for more than 5 years (Min: 65.2, Max: 111.8 months). The cumulative incidence of acute GVHD was 6.8 ± 2.9 and of chronic GVHD was 9.9 ± 3.6. Median time to ANC and platelet recovery was 16 days (range 9-37) and 29 days (range 15-180) respectively. Three patients acquired CMV infection after transplant. There was a significant impact of patient's age at diagnosis on the overall survival (Infantile: 100%, others: 45.6% ± 6.4%, P=0.016) and event free survival (Infantile: 100%, others: 40.6% ± 7.1%, P=0.013). Percentage of blasts at transplant, patients or donors gender, donor source and HLA disparity did not significantly affect OS or EFS.

show abstract

Section: Discussionsupporting

confidence: 76%

Factors Influencing the Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Single Institution Results from Saudi Arabia

Al‐Sweedan¹,

Siddiqui²,

Jafri³

et al. 2017

J Blood Lymph

View full text Add to dashboard Cite

show abstract

“…Umbilical cord and neonatal blood are enriched for immature hematopoieitic progenitors relative to adult blood (22); this has led to the development of cord blood banks for bone marrow transplantation (23). However, this explanation appears unlikely.…”

Section: Discussionmentioning

confidence: 99%

The rate of telomere sequence loss in human leukocytes varies with age

Frenck

Blackburn

Shannon

1998

Proc. Natl. Acad. Sci. U.S.A.

577

419

View full text Add to dashboard Cite

A gradual loss of telomeric repeat sequences with aging previously has been noted in normal adult tissues, and this process has been implicated in cell senescence. No data exist that address the rate of telomere shortening in normal human cells within families or early in life. To address these questions, we measured telomere lengths in peripheral blood leukocytes (PBLs) from 75 members of 12 families and in a group of unrelated healthy children who were 5-48 months old. Here we report the surprising observation that rates of telomere attrition vary markedly at different ages. Telomeric repeats are lost rapidly (at a rate of >1 kilobase per year) from the PBLs of young children, followed by an apparent plateau between age 4 and young adulthood, and by gradual attrition later in life. These data suggest that the loss of telomeric repeats in hematopoietic cells is a dynamic process that is differentially regulated in young children and adults. Our results have implications for current models of how telomeric sequences are lost in normal somatic cells and suggest that PBLs are an excellent tissue to investigate how this process is controlled.

show abstract

“…Since our initial preclinical (14)(15)(16) and clinical (1,(17)(18)(19) studies, there have been Ͼ2,000 CB transplants performed to treat a variety of malignant and nonmalignant disorders in children and adults (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(17)(18)(19). CB HSC͞HPC are frozen before use for transplantation (14,(20)(21)(22), but the longest that a CB collection has been stored frozen before use for clinical transplantation is in the 3-to 5-yr range.…”

mentioning

confidence: 99%

“…C ord blood (CB) is a viable alternative to bone marrow for related and unrelated allogeneic hematopoietic stem cell (HSC)͞progenitor cell (HPC) transplantation (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Since our initial preclinical (14)(15)(16) and clinical (1,(17)(18)(19) studies, there have been Ͼ2,000 CB transplants performed to treat a variety of malignant and nonmalignant disorders in children and adults (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(17)(18)(19).…”

mentioning

confidence: 99%

High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years

Broxmeyer

Srour

Hangoc

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

216

145

View full text Add to dashboard Cite

Transplanted cord blood (CB) hematopoietic stem cells (HSC) and progenitor cells (HPC) can treat malignant and nonmalignant disorders. Because long-term cryopreservation is critical for CB banking and transplantation, we assessed the efficiency of recovery of viable HSC͞HPC from individual CBs stored frozen for 15 yr. Average recoveries (؎ 1 SD) of defrosted nucleated cells, colony-forming unitgranulocyte, -macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E), and colony-forming unit-granulocyte, -erythrocyte, -monocyte, and -megakaryocyte (CFU-GEMM) were, respectively, 83 ؎ 12, 95 ؎ 16, 84 ؎ 25, and 85 ؎ 25 using the same culture conditions as for prefreeze samples. Proliferative capacities of CFU-GM, BFU-E, and CFU-GEMM were intact as colonies generated respectively contained up to 22,500, 182,500, and 292,500 cells. Self-renewal of CFU-GEMM was also retained as replating efficiency of single CFU-GEMM colonies into 2°dishes was >96% and yielded 2°colonies of CFU-GM, BFU-E, and CFU-GEMM. Moreover, CD34 ؉ CD38 ؊ cells isolated by FACS after thawing yielded >250-fold ex vivo expansion of HPC. To assess HSC capability, defrosts from single collections were bead-separated into CD34 ؉ cells and infused into sublethally irradiated nonobese diabetic (NOD)͞severe combined immunodeficient (SCID) mice. CD45 ؉ human cell engraftment with multilineage phenotypes was detected in mice after 11-13 wk; engrafting levels were comparable to that reported with fresh CB. Thus, immature human CB cells with high proliferative, replating, ex vivo expansion and mouse NOD͞SCID engrafting ability can be stored frozen for >15 yr, can be efficiently retrieved, and most likely remain effective for clinical transplantation.C ord blood (CB) is a viable alternative to bone marrow for related and unrelated allogeneic hematopoietic stem cell (HSC)͞progenitor cell (HPC) transplantation (1-13). Since our initial preclinical (14-16) and clinical (1, 17-19) studies, there have been Ͼ2,000 CB transplants performed to treat a variety of malignant and nonmalignant disorders in children and adults (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(17)(18)(19). CB HSC͞HPC are frozen before use for transplantation (14,(20)(21)(22), but the longest that a CB collection has been stored frozen before use for clinical transplantation is in the 3-to 5-yr range. With Ͼ100,000 CBs stored frozen world-wide for prolonged periods in anticipation of their clinical use, information on longer-term storage of CB HSC and HPC is of critical importance.The capacity to freeze and retrieve CB HPC cells was first reported when we suggested that CB could serve as a source of transplantable and engrafting HSC and HPC (14). We subsequently evaluated effects of 5-yr (16) and 10-yr (23) storage on retrieval of HPC in which postfreeze HPC numbers were compared directly to prefreeze numbers from the exact same CB samples. Thus, a true recovery rate could be calculated. At those times, we assessed only numbers and proliferation of HPC in vitro. In the present report, we extended anal...

show abstract

Outcome of Cord-Blood Transplantation from Related and Unrelated Donors

Abstract: Cord blood is a feasible alternative source of hematopoietic stem cells for pediatric and some adult patients with major hematologic disorders, particularly if the donor and the recipient are related.

Cited by 1,153 publications

References 25 publications

Factors Influencing the Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Single Institution Results from Saudi Arabia

Factors Influencing the Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Single Institution Results from Saudi Arabia

The rate of telomere sequence loss in human leukocytes varies with age

High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years

Contact Info

Product

Resources

About